Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

Rhea-AI Summary

Oruka Therapeutics (Nasdaq: ORKA) announced a proposed underwritten public offering of $500 million of common stock and, for certain investors, pre-funded warrants, with a 30-day underwriter option to purchase up to an additional $75 million. The offering is subject to market and other conditions and may not be completed.

Joint bookrunners include Leerink Partners, TD Cowen, Goldman Sachs, Stifel and Guggenheim; a Form S-3 shelf registration became effective April 10, 2026.

Positive

• Proposed $500 million underwritten offering announced
• Underwriters granted 30-day option for up to $75 million additional shares
• Major banks serving as joint bookrunning managers (Leerink, TD Cowen, Goldman Sachs, Stifel, Guggenheim)
• Form S-3 shelf registration effective April 10, 2026

Negative

• Offering subject to market and other conditions; completion not assured
• Issuance of common stock and pre-funded warrants implies potential dilution to existing shareholders

News Market Reaction – ORKA

-3.14%

21 alerts

-3.14% Session close to close

+63.7% Peak in 20 min

$4.26B Market Cap

0.2x Rel. Volume

In the Apr 28 session, ORKA declined 3.14%, reflecting a moderate negative market reaction. Argus tracked a peak move of +63.7% during that session. Our momentum scanner triggered 21 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement outlines a sizeable capital raise: a $500 million underwritten offering, plus a $7...

Analysis

This announcement outlines a sizeable capital raise: a $500 million underwritten offering, plus a $75 million over-allotment option, executed under an effective $1,000,000,000 Form S-3 shelf. It follows strong clinical and financial updates that lifted the stock near its 52-week high. Investors may track the final deal size, pricing versus the current $69.03 level, and future use of remaining shelf capacity.

Key Figures

Base offering size: $500 million Underwriters’ option: $75 million Shelf capacity: $1,000,000,000 +5 more

8 metrics

Base offering size $500 million Underwritten public offering of common stock and pre-funded warrants

Underwriters’ option $75 million 30-day option to purchase additional common shares

Shelf capacity $1,000,000,000 Maximum aggregate offering under Form S-3 shelf filed 2026-04-02

Registered resale shares 39,425,806 shares Shares of common stock covered by resale registration in 424B7

Shares outstanding 49,542,691 shares Common shares outstanding as of February 28, 2026 in 424B7

SILV Fund allocation 531,670 shares Shares listed for SILV Fund Ltd. in selling stockholder table

Reference price $68.87 per share Last reported sale price on April 20, 2026 in 424B7

S-3 reference price $50.43 per share Last reported sale price on April 1, 2026 in S-3 prospectus

Historical Context

5 past events · Latest: Mar 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 12	Earnings & pipeline	Positive	+25.0%	Strong cash position and clear timelines for EVERLAST-A and ORCA-SURGE.
Feb 09	Conference participation	Neutral	+0.6%	Multiple investor conference presentations and webcast availability.
Jan 12	Clinical data update	Positive	+10.2%	Positive Phase 1 ORKA-002 data and plans for Phase 2 psoriasis and HS trials.
Jan 06	JPM conference	Neutral	-1.0%	J.P. Morgan Healthcare Conference presentation announcement and webcast details.
Dec 11	Board changes	Neutral	-0.1%	New board member appointment and resignation of an existing director.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent clearly positive clinical and earnings updates have coincided with substantial upside moves.

Recent Company History

This announcement follows a series of value-building updates. In Dec 2025, Oruka added a commercially experienced board member. Early Jan 2026 brought positive Phase 1 data for ORKA-002 and trial progress for ORKA-001, with shares rising over 10%. The Mar 12, 2026 earnings and pipeline update, highlighting $479.6M in cash and advances in EVERLAST-A and ORCA-SURGE, saw a 25.04% gain. Today’s underwritten offering leverages this strengthened position and recent shelf registration.

Key Terms

underwritten public offering, pre-funded warrants, shelf registration statement, form s-3, +1 more

5 terms

underwritten public offering financial

"it has commenced an underwritten public offering of $500 million"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

pre-funded warrants financial

"in lieu of common stock to certain investors, pre-funded warrants"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

shelf registration statement regulatory

"A shelf registration statement on Form S-3 (File No. 333-294852)"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"A shelf registration statement on Form S-3 (File No. 333-294852)"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

prospectus supplement regulatory

"This offering is being made solely by means of a prospectus supplement"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MENLO PARK, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications, today announced that it has commenced an underwritten public offering of $500 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Oruka expects to grant the underwriters a 30-day option to purchase up to an additional $75 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the shares of common stock and pre-funded warrants are being offered by Oruka.

Leerink Partners, TD Cowen, Goldman Sachs & Co. LLC, Stifel and Guggenheim Securities are acting as joint bookrunning managers for the proposed offering. LifeSci Capital is acting as passive bookrunning manager for the proposed offering.

A shelf registration statement on Form S-3 (File No. 333-294852) relating to these securities has been filed with the Securities and Exchange Commission (the “SEC”) and became effective on April 10, 2026.  This offering is being made solely by means of a prospectus supplement and accompanying prospectus. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. A copy of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from: Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at prospectus-ny@ny.email.gs.com; Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at +1(415) 364-2720 or by email at syndprospectus@stifel.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Oruka

Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice per year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases.

Forward-Looking Statements

Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, concerning Oruka and other matters. These forward-looking statements include, but are not limited to, those relating to the anticipated size, terms and completion of the proposed offering. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “potential,” “pipeline,” “can,” “target,” “believe,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Oruka will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Oruka’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, market conditions and the satisfaction of closing conditions, as well as those uncertainties and factors described under the heading “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in Oruka’s most recent Annual Report on Form 10-K for the year ended December 31, 2025, the preliminary prospectus supplement and accompanying prospectus relating to the offering and any subsequent filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of Oruka’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth therein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Oruka does not undertake or accept any duty to make any updates or revisions to any forward-looking statements, except as required by applicable law. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in Oruka.

Investor Contact:

Alan Lada
(650) 606-7911
alan.lada@orukatx.com

FAQ

What is Oruka Therapeutics (ORKA) offering in the April 27, 2026 proposal?

Oruka is proposing an underwritten public offering of $500 million of common stock and pre-funded warrants. According to Oruka, underwriters may buy up to an additional $75 million within a 30-day option period.

Who are the underwriters for Oruka Therapeutics' (ORKA) proposed offering?

Joint bookrunning managers include Leerink Partners, TD Cowen, Goldman Sachs, Stifel, and Guggenheim. According to Oruka, LifeSci Capital is acting as passive bookrunning manager for the offering.

Is Oruka’s (ORKA) proposed $500 million offering guaranteed to close?

No, the offering is not guaranteed to close; it is subject to market and other conditions. According to Oruka, there can be no assurance as to whether or when the offering may be completed.

Where can investors find the prospectus for Oruka Therapeutics (ORKA) offering?

A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and available on its website. According to Oruka, copies will also be obtainable from the listed underwriters when available.

Will Oruka Therapeutics (ORKA) use a registration statement for this offering?

Yes, the offering is covered by a Form S-3 shelf registration that became effective April 10, 2026. According to Oruka, the securities are being offered solely by a prospectus supplement and accompanying prospectus.